

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Lars HOLMGREN et al. Conf.:
Appl. No.: NEW Group:
Filed: November 25, 2003 Examiner:
For: ANGIOGENESIS RELATED MOLECULES

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 25, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
09/332,063

U.S. Filing Date(s)
June 14, 1999

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977
P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

BS
GMM/TBS/mua
0552-0154P

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 09/30/03)

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
0552-0154PAPPLICATION NO.
New
Divisional of
09/332,063APPLICANT
Lars HOLMGREN et al.FILING DATE
November 25, 2003

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US 5,679,350		1997-10-21	Jankun et al.			
	US 5,916,572		1999-06-29	Reed et al.			
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
EP	0 206 400	A1	1986-12-30	EPO				

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	CLAESSON-WELSH et al., Proc. Natl. Acad. Sci. USA, Vol. 95, May 1998, pages 5579-5583.
	O'REILLY et al., Nature Medicine, Vol., 2, No. 6, June 1996, pages 689-692.
	Wilson et al., Nature, Vol. 368, March 3, 1994, pages 32-38.
	Moser, Tammy L. et al. Proc. Natl. Acad. Sci. USA, Vol. 96, No. 6, pp. 2811-2816, March 16, 1999.
	Claesson-Welsh, Lena, Proc. Natl. Acad. Sci. USA, Vol. 95, No. 10, pp.5579-5583, May 12, 1998.
	Kost, Christine et al. Eur. J. Biochem, Vol. 236, No. 2, pp.682-688, March 1, 1996.
	Database EMSTS Accession No. G16015, January 25, 1996, Murray M. et al. XP002121366.
	Petersen, T. et al., Characterization of the Gene for Human Plasminogen, a Key Proenzyme in the Fibrinolytic System. J. of Biol. Chem. 205(11):6104-6111, 1990.
	Amino acid database, Accession #013028, 1997.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	ATTY. DOCKET NO. 0552-0154P	APPLICATION NO. New Divisional of 09/332,063
	APPLICANT Lars HOLMGREN et al.	
	FILING DATE November 25, 2003	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	Amino acid database, Accession #W00024, 1997.
	Schwartz et al., A superactive insulin: [B10-Aspartic acid] insulin (human), Proc. Natl. Acad. Sci. 84:6408-6411, 1987.
	Lin et al. Structure-Function Relationships in Glucagon: Properties of Highly Purified Des-His(1)-, Monoiodo-, [Des-Asn (28), Thr (29)] (homoserine lactone (27)-glucagon. Biochemistry 14(8):1559-1563, 1975.
	Biotechnology Industry Organization, Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, 1994.
	Bork, Peer, Gene Research, 10, pages 3398-3400, 2000.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	